DGAP-News: SHS Gesellschaft für Beteiligungsmanagement mbH / Key word(s): Investment/Private Equity
SHS invests in Swiss-German specialty drug company Develco Pharma
17.12.2020 / 09:00
SHS invests in Swiss-German specialty drug company Develco Pharma
Tübingen-based industry investor SHS acquires minority share in formulation specialist Develco Pharma
Develco specializes in the development, approval and production of innovative and generic specialty drugs and offers a unique and broad set of formulation technologies for orally administered medicines with specific substance-release profiles
Develco operates a state-of-the-art production facility of its own in Germany
Equity investment accelerates the development of new medicines
Tübingen, Germany, December 17, 2020
Tübingen-based SHS Gesellschaft für Beteiligungsmanagement mbH is investing from its SHS V fund in the Swiss-German specialty drug company Develco Pharma. Founded in 2006 and now with more than 120 employees,